


RESEARCH ARTICLES

Open Access



# Mild hypothermia combined with dexmedetomidine reduced brain, lung, and kidney damage in experimental acute focal ischemic stroke

Denise Battaglini<sup>1,2,3</sup>, Adriana Lopes da Silva<sup>3</sup>, Nathane Santanna Felix<sup>3</sup>, Gisele Rodrigues<sup>3</sup>, Mariana Alves Antunes<sup>3</sup>, Nazareth Novaes Rocha<sup>3,4</sup>, Vera Luiza Capelozzi<sup>5</sup>, Marcelo Marcos Morales<sup>6</sup>, Fernanda Ferreira Cruz<sup>3</sup>, Chiara Robba<sup>1,7</sup>, Pedro Leme Silva<sup>3</sup>, Paolo Pelosi<sup>1,7</sup> and Patricia Rieken Macedo Rocco<sup>3,8\*</sup> 

\*Correspondence:  
prmrocco@biof.ufrj.br

<sup>3</sup> Laboratory of Pulmonary Investigation, Carlos Chagas Filho Institute of Biophysics, Centro de Ciências da Saúde, Federal University of Rio de Janeiro, Avenida Carlos Chagas Filho, 373, Bloco G-014, Ilha Do Fundão, Rio de Janeiro, RJ 21941-902, Brazil  
Full list of author information is available at the end of the article

## Abstract

**Background:** Sedatives and mild hypothermia alone may yield neuroprotective effects in acute ischemic stroke (AIS). However, the impact of this combination is still under investigation. We compared the effects of the combination of mild hypothermia or normothermia with propofol or dexmedetomidine on brain, lung, and kidney in experimental AIS. AIS-induced Wistar rats ( $n = 30$ ) were randomly assigned, after 24 h, to normothermia or mild hypothermia (32–35 °C) with propofol or dexmedetomidine. Histologic injury score and molecular biomarkers were evaluated not only in brain, but also in lung and kidney. Hemodynamics, ventilatory parameters, and carotid Doppler ultrasonography were analyzed for 60 min.

**Results:** In brain: (1) hypothermia compared to normothermia, regardless of sedative, decreased tumor necrosis factor (TNF)- $\alpha$  expression and histologic injury score; (2) normothermia + dexmedetomidine reduced TNF- $\alpha$  and histologic injury score compared to normothermia + propofol; (3) hypothermia + dexmedetomidine increased zonula occludens-1 expression compared to normothermia + dexmedetomidine. In lungs: (1) hypothermia + propofol compared to normothermia + propofol reduced TNF- $\alpha$  and histologic injury score; (2) hypothermia + dexmedetomidine compared to normothermia + dexmedetomidine reduced histologic injury score. In kidneys: (1) hypothermia + dexmedetomidine compared to normothermia + dexmedetomidine decreased syndecan expression and histologic injury score; (2) hypothermia + dexmedetomidine compared to hypothermia + propofol decreased histologic injury score.

**Conclusions:** In experimental AIS, the combination of mild hypothermia with dexmedetomidine reduced brain, lung, and kidney damage.

**Keywords:** Neuroprotection, Hypothermia, Ischemic stroke, Animal model, Kidney

## Background

Stroke is a leading cause of long-term disability, impaired quality of life, and mortality worldwide [1]. Focal ischemic stroke can enhance leukocyte infiltration, increasing the production of toxic metabolites capable of destroying the blood–brain barrier and leading to cell death [2]. Stroke has also been associated with systemic inflammation, which may lead to distal organ damage [2, 3].

Novel therapies have been proposed for neuroprotection in stroke patients. Dexmedetomidine (an  $\alpha_2$ -adrenergic agonist) and propofol (2,6-diisopropylphenol) seem to decrease the cerebral metabolic rate, without compromising cerebral autoregulation, and exert anti-inflammatory, antioxidant, and anti-apoptotic properties [4, 5]. Mild hypothermia may also induce neuroprotection in experimental studies [6, 7]; however, there are controversies in human clinical trials [8, 9]. Sedatives (such as propofol or dexmedetomidine) and mild hypothermia alone have been shown to present neuroprotective effects and reduce brain damage [10]. However, the impact of this combination is still under investigation in both pre-clinical and clinical settings [11, 12].

This study aimed to compare the effects of the combination of mild hypothermia or normothermia with propofol or dexmedetomidine on brain, lung, and kidney in experimental acute focal ischemic stroke, reproducing an intensive care unit scenario regarding the use of controlled mechanical ventilation, as well as continuous hemodynamic and respiratory monitoring [13].

## Materials and methods

### Study approval

This study was approved by the Ethics Committee for the Use of Animals (CEUA-CCS-116/19) of Federal University of Rio de Janeiro, Brazil. All animals received care in accordance with the “Principles of Laboratory Animal Care”, formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” from the National Academy of Sciences, USA. Animal experiments were performed in compliance with ARRIVE guidelines<sup>13</sup>.


### Animal preparation and the experimental protocol

Thirty male Wistar rats (body weight, 359–420 g) were anesthetized with xylazine 2.5 mg kg<sup>-1</sup> and ketamine 75 mg.kg<sup>-1</sup> intraperitoneally (i.p.), placed in a stereotactic frame with their heads immobilized, and then underwent acute focal ischemic stroke by thermocoagulation of the pial blood vessels that cover the somatosensory, motor and primary sensorimotor cortex [2]. The procedure consists of craniotomy after the skin incision, exposing the left frontoparietal cortex (+2 to –6 mm antero-posterior based on the bregma). Transdural thermocoagulation of blood in the superficial vessels was performed by approaching with a hot probe adjusted to 300 °C [2]. Vessel lesions were evaluated macroscopically through the color changes after 5 min. The incision tissue was sutured, the animals were kept warm under a heating lamp, and oxygen was administered (fraction of inspired oxygen [FiO<sub>2</sub>] of 0.3) during and after the surgical procedure. After recovery from anesthesia, the animals were returned to their cages. The stroke

procedure was performed by the same experienced investigator (A.L.S.), enabling the same stroke severity pattern. Tramadol ( $10 \text{ mg kg}^{-1}$ ) was administered intramuscularly to relieve pain every 8 h for 24 h [2].

After 24 h, animals were anesthetized (sodium thiopental  $50 \text{ mg kg}^{-1}$ , i.p.), and an intravenous (i.v.) catheter (Jelco 24G; Becton, Dickinson and Company, USA) was inserted into the tail vein, and continuous anesthesia was initiated (T0) [14]. After reaching an adequate depth of anesthesia, animals were tracheostomized, and another catheter (18G; Arrow International, USA) placed in the right internal carotid artery for arterial blood gas analysis (ABL80 FLEX; Radiometer Medical, Denmark). Mean arterial pressure (MAP) and rectal temperature were monitored continuously (Networked Multiparameter Veterinary Monitor Life Window 6000 V; Digicare Animal Health, Florida, USA). The core temperature was measured continuously through the right internal carotid artery (CCA) using a PiCCO catheter (PV2013L07-A; Pulsion Medical Systems, Feldkirchen, Germany). Neuromuscular blockade was achieved with pancuronium bromide ( $1 \text{ mg kg}^{-1}$  i.v.). Animals were then mechanically ventilated (Servo-I; MAQUET, Solna, Sweden) in volume-controlled mode, with  $V_T = 6 \text{ ml kg}^{-1}$ , respiratory rate =  $80 \text{ breaths min}^{-1}$ ,  $\text{FiO}_2 = 0.4$ , and positive end-expiratory pressure (PEEP) =  $3 \text{ cmH}_2\text{O}$ . Air-flow and airway pressure were recorded continuously using a computer running custom-made software (LabVIEW; National Instruments, Austin, TX, USA) [15, 16]. Tidal volume, respiratory system plateau pressure (Pplat, RS) and driving pressure ( $\Delta P$ , RS) were measured [2, 15] (MATLAB, version R2007a; MathWorks Inc, Natick, MA, USA).

After hemodynamic and respiratory stabilization, the animals were randomly assigned to normothermia or mild hypothermia combined with propofol or dexmedetomidine: NORMO + PRO, HYPO + PRO, NORMO + DEX, HYPO + DEX groups ( $n = 6$ , each) (Fig. 1A). After AIS induction, animals from the control (CTRL) group were evaluated under normothermia. They were then anesthetized with sodium thiopental ( $50 \text{ mg kg}^{-1}$ ) and protectively mechanically ventilated. CTRL animals were then compared to the randomized groups for molecular biomarkers. To maintain the core temperature between  $37.8^\circ\text{C}$  and  $38.3^\circ\text{C}$  [17] (normothermia), animals were warmed using a thermostatically controlled heating pad (EFF 421, Insight; Brazil) and an infrared light positioned 30 cm from the body of the rat to reach a normothermic condition. The hypothermia protocol was induced by spraying 75% alcohol on the rats' body until a stable temperature compatible with mild hypothermia (between  $34^\circ\text{C}$  and  $35^\circ\text{C}$ ) was reached [10, 18, 19]. Temperature stabilization was achieved after 10 min (T1) and the animals then received dexmedetomidine (Precedex; Laboratories Abbott do Brasil Ltda., São Paulo, SP, Brazil) with a bolus of  $5 \mu\text{g kg}^{-1}$  i.v. for 10 min and then an infusion of  $0.1\text{--}0.5 \mu\text{g kg}^{-1} \text{ h}^{-1}$  i.v. for 50 min or propofol (Propovan; Laboratories Cristália from Brazil Ltda., Itapira, São Paulo, SP, Brazil) via an initial infusion of  $100\text{--}200 \mu\text{g kg}^{-1} \text{ min}^{-1}$  i.v. for 10 min and then infusion of  $100\text{--}400 \mu\text{g kg}^{-1} \text{ min}^{-1}$  i.v. for 50 min. Both infusion rates were based on previous studies that showed no adverse hemodynamic effects in rats during infusion for 60 min [2, 14]. Animals were kept at normothermia or hypothermia until the end of the experiment (T3). At T3, all animals received heparin (1000 IU) intravenously into the tail vein and euthanized by an overdose of sodium thiopental ( $150 \text{ mg kg}^{-1}$ ). Brain, lungs, and kidneys were carefully removed for histology and molecular biology analysis. Histology of the heart was also performed. Data on hemodynamics, gas exchange, and



**Fig. 1** Schematic flowchart of the study design (top) and timeline representation of the experimental protocol (bottom). **A** Animals were randomly assigned to normothermia (NORMO) or mild hypothermia (HYPO) combined with propofol (PRO) or dexmedetomidine (DEX): NORMO + PRO, HYPO + PRO, NORMO + DEX, HYPO + DEX groups ( $n = 6$ , each). **B** Study timeline from the time of stroke induction to the end of the experimental protocol. BGA blood gas analysis, cCT continuous core temperature, cD carotid Doppler, cMAP continuous mean arterial pressure, cRT continuous rectal temperature, T0 baseline, T1, T2, and T3 = 15, 30, and 60 min after temperature stabilization

respiratory system mechanics were collected at T0, T1, T2, and T3 (Fig. 1B). We opted to focus on our primary hypothesis, which was to compare the effects of the combination of mild hypothermia or normothermia with propofol or dexmedetomidine on brain, lung, and kidney in experimental acute ischemic stroke. No *sham* animals were included in the current study. All data regarding *sham* animals were previously produced by our laboratory and published elsewhere [2]. The resulting reduction of the number of groups led to a more reliable statistical analysis.

### Carotid Doppler ultrasonography

Phased-arrayed ultrasonography was performed using a miniaturized probe and a color-coded and duplex Doppler ultrasonographic system (Samsung UGEO HM70 system; São Paulo, SP, Brazil) with an 8–13 MHz linear transducer. The assessments were performed with the rats in the supine position. The probe was directed parallel to the blood stream, and the angle was maintained at  $< 20^\circ$ . All ultrasonic readings were evaluated and appraised by two investigators with experience in carotid sonography (N.R. and D.B.).

Carotid Doppler ultrasonography [20] of both CCAs was performed at T0 and from the left CCA at T1 and T3 (Fig. 1B). The peak systolic velocity (PSV) ( $\text{cm s}^{-1}$ ), end-diastolic velocity (EDV) ( $\text{cm s}^{-1}$ ), mean flow velocity (mFV) (extrapolated from the following formula:  $\text{mFV} = \text{SFV} + 2 \times \text{EDV}/3$ ), where SFV is the systolic flow velocity [21], pressure gradient ( $\text{PG} = 4V^2$ ) [22–24], and the pulsatility index (PI) ( $\text{PI} = (\text{PSV} - \text{EDV})/\text{MV}$ ) were calculated.

### Histologic injury score

Tissues from the brain (perilesional area [penumbra] located in the right hemisphere of the ischemic lesion), left lung, right kidney, and heart were extracted, fixed in 4% paraformaldehyde for 24 h, and embedded in paraffin. Tissue section (5  $\mu\text{m}$  thick) were cut (Leica RM2135 Leica Biosystem, São Paulo, Brazil) and stained with hematoxylin and eosin. Eight fields of view per section were studied through a light microscope (Olympus BX51; Olympus Latin America, Brazil), at  $\times 25$ ,  $\times 100$ ,  $\times 400$  and  $\times 1000$  magnification. Perilesional brain, lung, kidney, and heart injury scores were quantified using a scale to represent the severity of apoptosis, edema, inflammation, and necrosis (0, no effect; 4, maximum severity). The extension of each feature was graded as 0 for no appearance and 4 for complete involvement. Final scores were calculated as the product of severity and extent of each feature, ranging from 0 to 16. The cumulated brain, lung, kidney, and heart injury score ranged from 0 to 64 [25]. All histological analyses were performed by two investigators (G.R. and V.L.C.), blinded to the group allocation. The scores of each expert were combined to yield a final score by arithmetic averaging [25]. The value of kappa was 0.86.

### Molecular biomarkers in brain, lung, and kidney tissues

A small specimen of the brain tissue (about 3–4 mm) was collected for the molecular biomarker analysis from the rectangular perilesional area (*penumbra*), located medially to the right hemisphere of ischemic lesion. Additionally, the right lung, and left kidney tissues were extracted, quickly frozen and stored at  $-80^\circ\text{C}$ . RT-PCR was performed to measure molecular biomarkers associated with inflammation (tumor necrosis factor [TNF]- $\alpha$ , interleukin [IL]-1 $\beta$ ), endothelial cell damage (intercellular adhesion molecule-1 [ICAM-1]) and tight junction protein zonula occludens-1 (ZO-1) (a biomarker that establishes a link between the transmembrane protein occludin and the actin cytoskeleton) in perilesional brain tissue. The expression of proinflammatory markers (TNF- $\alpha$  and IL-6), ICAM-1 and a molecular biomarker associated with inflammation and fibrosis (E-selectin) were evaluated in central slices of right lung tissue. The expression of kidney injury molecule (KIM)-1 (a biological biomarker associated with kidney injury), IL-6, syndecan (a heparan sulfate proteoglycan associated with tubular epithelial cell damage), and ZO-1 was evaluated in the kidney tissue. Total RNA was extracted from brain, lung, and kidney frozen tissues with the ReliaPrep RNA Tissue Miniprep System (Promega Corporation, Fitchburg, Wisconsin, USA), following the manufacturer's recommendations. RNA concentration was measured by spectrophotometry in a Nanodrop ND-2000 system (Thermo Fisher Scientific, Wilmington, DE, USA). First-strand cDNA was synthesized from total RNA using the High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher, Waltham, MA, USA). Relative mRNA levels were measured with a

BRYT Green system (Promega, Fitchburg, WI, USA) using PCR Mastercycler ep Realplex Eppendorf (Eppendorf, Hamburg, Germany). Samples were measured in triplicate. The primers are shown in Table 1.

For each sample, the expression of each gene was normalized to the acidic ribosomal phosphoprotein P0 (36B4) housekeeping gene and expressed as the fold change relative to CTRL, using the  $2^{-\Delta\Delta C_t}$  method, where  $\Delta C_t = C_t$  (target gene) –  $C_t$  (reference gene) [26]. Blinded analyses were carried out by one investigator (M.A.A.).

### Statistical analysis

The sample size was calculated based on pilot studies to allow detection of differences between mild hypothermia and normothermia in TNF- $\alpha$  expression in brain-injured rats, regardless of the sedative used. The number of animals per group ( $n=6$ ) was calculated based on a power of 80%,  $\alpha=5\%$ , two-tailed, and effect size ( $d$ ) of 1.37 (G\*Power 3.1.9.2; University of Düsseldorf, Düsseldorf, Germany). The primary outcome was TNF- $\alpha$  expression in brain tissue, and the secondary outcomes were brain, lung, and

**Table 1** Forward and reverse oligonucleotide sequences of target gene primers

Gene	Primer	Primer sequences (5'–3')
Brain		
TNF- $\alpha$	Forward	CAGCCGATTGCGCATTCATAC
	Reverse	GGCTCTGAGGAGTAGACGATAA
IL-1 $\beta$	Forward	CTATGTCTTGCCCGTGGAG
	Reverse	CATCATCCACAGAGTCACA
ICAM-1	Forward	CTCCGACTAGGGTCCTGAA
	Reverse	CTTCAGAGGCAGGAACAGG
ZO-1	Forward	CACCACAGACATCCAACAG
	Reverse	CACCAACCACTCTCCCTTGT
Lung		
IL-6	Forward	CTCCGCAAGAGACTTCCAG
	Reverse	CTCCTCTCCGACTTGTGA
TNF- $\alpha$	Forward	CAGCCGATTGCGCATTCATAC
	Reverse	GGCTCTGAGGAGTAGACGATAA
E-selectin	Forward	TGCCAAGAACAGGAATACCC
	Reverse	CTCCAGGATTTGAGGAACA
ICAM-1	Forward	CTCCGACTAGGGTCCTGAA
	Reverse	CTTCAGAGGCAGGAACAGG
Kidney		
KIM-1	Forward	GAAGAAAACAATGGATCAAGGGAT
	Reverse	GGAGTGGAAATGGCTCTAATGAAC
ZO-1	Forward	CACCACAGACATCCAACAG
	Reverse	CACCAACCACTCTCCCTTGT
Syndecan	Forward	GTTCCGCTGTTTGTGTGTTT
	Reverse	GATGAAGGCTGTCCAGGTA
IL-6	Forward	CTCCGCAAGAGACTTCCAG
	Reverse	CTCCTCTCCGACTTGTGA
36B4	Forward	GGATCACTCAGGAGCAGGAG
	Reverse	CTTGCACTCAAGGGAAGG

TNF tumor necrosis factor, ICAM intercellular adhesion molecule, ZO-1 zonula occludens-1, KIM kidney injury molecule-1, IL-6 interleukin-6, IL-1 $\beta$  interleukin-1 beta, 36B4 acidic ribosomal phosphoprotein P0

kidney histology and molecular biology. Data were tested for normality using the Kolmogorov–Smirnov test with Lilliefors' correction, and the Levene median test was used to evaluate homogeneity of variances. Differences in the parameters among the groups and over time were compared using the two-way ANOVA test followed by the Holm–Šídák post hoc test or two-way ANOVA for non-parametric data with Tukey's multiple comparison. Significance was established at  $p < 0.05$ . For histologic and molecular biology variables, Mann–Whitney test followed by the Bonferroni multiple comparisons were done.  $p$  value ( $p < 0.0125$ ) was adjusted for four comparisons: hypothermia + dexmedetomidine, normothermia + dexmedetomidine, hypothermia + propofol, and normothermia + propofol. Parametric data were expressed as means  $\pm$  SD and non-parametric data as medians (interquartile range). All statistical analyses were performed using SPSS version 23.0 and GraphPad version 8.2.1.

## Results

### Hemodynamics and respiratory function during the experiments

MAP remained higher than 80 mmHg in all groups. In T1, MAP was significant higher ( $p = 0.02$ ) in hypothermia + propofol compared to hypothermia + dexmedetomidine.

In the right common carotid artery, at T0, PSV and PG were higher in hypothermia + dexmedetomidine compared to normothermia + dexmedetomidine (PSV  $p = 0.009$  and PG  $p = 0.002$ ) (Table 2). In the left common carotid artery, at T0, PSV, EDV and MV were higher in hypothermia + dexmedetomidine compared to normothermia + dexmedetomidine (PSV  $p = 0.039$ , EDV  $p = 0.018$ , and MV  $p = 0.022$ , respectively). At T0, EDV was higher in hypothermia + dexmedetomidine compared to hypothermia + propofol (EDV  $p = 0.036$ ). At T1 and T3, PSV and MV were higher in hypothermia + propofol compared to normothermia + propofol (PSV T1  $p = 0.041$ ; PSV T3  $p = 0.029$ ; MV T1,  $p = 0.040$ ; MV T3  $p = 0.031$ ). At T1 and T3, MV was higher in hypothermia + dexmedetomidine compared to normothermia + dexmedetomidine (MV T1  $p = 0.042$ ; MV T3  $p = 0.042$ ). PG and PI did not differ among the groups at any time (Table 2).

At T0 and T1, Pplat, RS was higher in hypothermia + propofol compared to normothermia + propofol (Pplat, RS T0  $p = 0.026$ ; T1  $p = 0.008$ ) (Table 3). No significant differences were found in  $V_T$  and  $\Delta P$ , RS (Table 3) as well as gas exchange between groups (Table 4).

### Perilesional brain tissue

The mRNA expression of molecular biomarkers in the perilesional brain tissue is reported in Fig. 2. TNF- $\alpha$  expression was lower in normothermia + dexmedetomidine versus normothermia + propofol ( $p = 0.002$ ); and in hypothermia + dexmedetomidine versus normothermia + dexmedetomidine and normothermia + propofol ( $p = 0.003$ ). ZO-1 expression was higher in hypothermia + dexmedetomidine compared to normothermia + dexmedetomidine ( $p = 0.002$ ).

Photomicrographs of perilesional area in each group are shown in Fig. 3A. The brain histologic injury score, which includes the extent and severity of apoptosis, edema, inflammation, and necrosis, is presented in Table 5 and Fig. 3B. The brain injury score was lower in normothermia + dexmedetomidine and hypothermia + propofol versus normothermia + propofol ( $p = 0.002$ , both); and in hypothermia + dexmedetomidine versus normothermia + dexmedetomidine ( $p = 0.002$ ).



**Table 2** Ultrasound of common carotid arteries

Ultrasound parameter	Group		T0	T1	T3	Group effect	Time effect	Group × time effect
Left carotid								
PSV (cm/s)	NORMO	DEX	56.42 (45.21–82.28)	64.01 (55.38–95.68)	81.78 (61.15–100.70)	$p=0.005$	$p<0.001$	$p=0.429$
		HYPO	80.18 (70.66–90.35)	91.03 (81.68–95.84)	96.27 (94.47–104.90)			
	NORMO	PRO	61.25 (57.60–70.38)	66.39 (61.14–73.64)	73.93 (65.11–75.91)			
		HYPO	79.92 (64.60–91.56)	87.49 (80.64–90.90)	90.43 (85.73–100.20)			
EDV (cm/s)	NORMO	DEX	3.67 (2.63–6.11)	5.36 (3.84–6.77)	6.29 (4.99–7.50)	$p=0.019$	$p<0.001$	$p=0.556$
		HYPO	7.74 (5.49–10.18)	8.93 (6.01–9.59)	9.93 (6.54–10.09)			
	NORMO	PRO	3.92 (2.90–4.71)	3.97 (3.01–5.93)	5.62 (4.56–6.76)			
		HYPO	4.39 (3.71–6.59)	5.83 (4.22–7.35)	7.22 (5.15–7.78)			
MV (cm/s)	NORMO	DEX	59.31 (47.38–85.28)	67.24 (58.29–101.10)	85.98 (64.52–105.00)	$p=0.003$	$p<0.001$	$p=0.425$
		HYPO	84.21 (76.71–95.30)	97.33 (85.77–101.60)	102.90 (101.30–109.20)			
	NORMO	PRO	64.32 (59.62–73.17)	69.34 (63.33–77.38)	69.34 (63.33–77.38)			
		HYPO	82.85 (67.90–95.13)	90.88 (85.54–94.47)	95.24 (90.13–102.70)			
PG (mmHg)	NORMO	DEX	1.38 (0.93–1.93)	1.77 (1.09–2.79)	2.72 (1.55–3.32)	$p=0.122$	$p<0.001$	$p=0.636$
		HYPO	2.08 (1.81–3.07)	2.68 (1.91–3.23)	3.60 (3.00–3.89)			
	NORMO	PRO	1.40 (1.26–1.71)	1.82 (1.57–2.24)	2.27 (1.82–2.88)			
		HYPO	1.39 (0.77–1.92)	1.87 (1.28–2.60)	2.45 (1.89–3.38)			
PI	NORMO	DEX	2.46 (2.30–2.78)	2.59 (2.43–3.61)	2.95 (2.70–3.86)	$p=0.213$	$p<0.001$	$p=0.696$
		HYPO	2.93 (2.39–4.13)	3.19 (2.91–4.22)	3.63 (3.46–4.33)			
	NORMO	PRO	2.74 (2.49–3.16)	2.98 (2.70–3.31)	3.06 (2.96–3.35)			
		HYPO	2.81 (2.66–2.98)	2.98 (2.91–3.49)	3.62 (2.99–3.84)			



**Table 2** (continued)

Ultrasound parameter	Group	T0	T1	T3	Group effect	Time effect	Group × time effect
Right carotid							
PSV (cm/s)	NORMO	DEX	49.93 (44.70–64.81)	–	–	T0 HYPO-DEX vs NORMO-DEX, $p = 0.009$	
	HYPO		70.30 (64.86–83.90)	–	–		
	NORMO	PRO	53.85 (39.73–60.27)	–	–		
	HYPO		55.42 (48.35–64.20)	–	–		
EDV (cm/s)	NORMO	DEX	5.39 (3.76–6.21)	–	–	–	
	HYPO		8.26 (5.68–10.74)	–	–		
	NORMO	PRO	4.87 (4.05–5.28)	–	–		
	HYPO		3.66 (2.75–6.05)	–	–		
MV (cm/s)	NORMO	DEX	52.67 (48.01–68.79)	–	–	–	
	HYPO		77.13 (69.81–87.74)	–	–		
	NORMO	PRO	57.48 (42.88–63.14)	–	–		
	HYPO		57.87 (50.30–68.86)	–	–		
PG (mmHg)	NORMO	DEX	1.98 (1.86–2.14)	–	–	T0 HYPO-DEX vs NORMO-DEX, $p = 0.002$	
	HYPO		3.12 (2.78–4.43)	–	–		
	NORMO	PRO	2.12 (1.89–2.84)	–	–		
	HYPO		1.83 (1.65–2.69)	–	–		
PI	NORMO	DEX	2.91 (2.30–3.37)	–	–	–	
	HYPO		3.40 (2.95–4.14)	–	–		
	NORMO	PRO	2.98 (2.27–3.67)	–	–		
	HYPO		2.87 (2.48–3.19)	–	–		

Values are presented as medians (interquartile range) of 6 animals/group. PSV peak systolic velocity, EDV end-diastolic velocity, MV mean velocity, PG pressure gradient, PI Pulsatility Index of left and right common carotid arteries (CCA) at T0, T1, and T3. Two-way ANOVA test with Tukey's multiple comparison was used for the left carotid over time, considering significance at  $p < 0.05$ ; Mann–Whitney test was adopted for the right carotid at baseline, assuming significance at  $p < 0.0125$ . PSV in the right carotid at T0 was higher in mild hypothermia + dexmedetomidine (HYPO-DEX) than normothermia + dexmedetomidine (NORMO-DEX),  $p = 0.009$ . No differences at T0 in EDV and PI in the right CCA were found among the groups. At T0, PG was significantly higher in HYPO-DEX than NORMO-DEX in the right CCA

**Table 3** Respiratory mechanics

Parameter	Group	T0	T1	T2	T3	Group effect	Time effect	Group vs. time effect
$V_T$ (mL/kg)						$p=0.246$	$p=0.132$	$p=0.174$
NORMO	DEX	6.67 (5.91–7.12)	6.67 (6.21–7.12)	6.90 (6.55–7.97)	6.67 (6.19–7.59)			
HYPO		7.35 (7.04–7.94)	7.73 (7.10–8.65)	7.48 (7.10–8.47)	7.94 (7.59–8.62)			
NORMO	PRO	6.84 (6.39–7.76)	6.76 (6.32–7.77)	7.00 (6.62–7.83)	7.13 (6.60–7.88)			
HYPO		7.73 (6.31–9.46)	7.51 (6.31–8.14)	8.34 (7.29–9.14)	7.50 (7.05–7.69)			
$P_{plat}$ , RS (cmH <sub>2</sub> O)						$p=0.003$	$p=0.020$	$p=0.961$
NORMO	DEX	14.10 (11.45–15.65)	14.20 (11.40–15.55)	16.10 (1.93–16.30)	14.80 (12.45–16.80)	T0 HYPO-PRO vs NORMO-PRO, $p=0.026$		
HYPO		14.30 (12.90–16.72)	16.15 (14.39–16.73)	15.90 (13.55–17.10)	16.45 (15.23–16.80)	T1 HYPO-PRO vs NORMO-PRO, $p=0.008$		
NORMO	PRO	9.25 (8.80–11.19)	11.03 (8.65–11.93)	11.50 (9.90–12.05)	11.10 (9.28–13.30)			
HYPO		13.84 (12.20–15.43)	15.24 (13.10–16.80)	14.55 (13.05–16.30)	14.40 (11.70–16.80)			
$\Delta P$ , RS (cmH <sub>2</sub> O)						$p=0.017$	$p<0.001$	$p=0.476$
NORMO	DEX	11.00 (8.00–12.10)	10.50 (8.80–12.00)	12.80 (9.18–13.30)	11.50 (9.90–14.40)			
HYPO		10.75 (9.20–12.93)	12.68 (11.35–13.08)	12.55 (9.85–14.51)	12.70 (11.50–16.76)			
NORMO	PRO	6.25 (5.78–7.59)	8.08 (6.03–9.03)	9.15 (8.38–9.65)	9.45 (8.95–10.78)			
HYPO		9.99 (8.63–12.45)	11.44 (9.53–13.22)	10.87 (9.41–13.29)	10.65 (8.38–13.23)			

Data are expressed as medians (interquartile range) of 6 animals/group. Two-way ANOVA for non-parametric data was used with Tukey's multiple comparison,  $p$  was considered statistically significant for values  $<0.05$ . At T3, Mann–Whitney test was used with Bonferroni comparison, considering  $p<0.0125$  as significant, but no significant differences were found. *HYPO* mild hypothermia, *NORMO* normothermia, *PRO* propofol, *DEX* dexmedetomidine,  $V_T$  tidal volume,  $P_{plat}$  plateau pressure, *RS* respiratory system,  $\Delta P$  driving pressure

### Distal organs: lung, kidney, and heart

In lung, the gene expression of TNF- $\alpha$  was significantly lower in hypothermia + propofol compared to normothermia + propofol ( $p=0.002$ ) (Fig. 2). The expression of IL-6, ICAM-1, and E-selectin did not differ between the groups. In kidney, the expression of syndecan was lower in hypothermia + dexmedetomidine than normothermia + dexmedetomidine ( $p=0.009$ ), and no significant differences were observed in the expression of KIM-1, IL-6, and ZO-1.

Figure 3A shows the photomicrographs of lung and kidney parenchyma in all groups. The lung histologic injury score was significantly lower in normothermia + dexmedetomidine than normothermia + propofol or hypothermia + propofol ( $p=0.002$ , both), as well as in hypothermia + dexmedetomidine compared to hypothermia + propofol ( $p=0.002$ ) (Table 5, Fig. 3B). The kidney histologic injury score was significantly lower in hypothermia + dexmedetomidine than normothermia + dexmedetomidine ( $p=0.007$ ) and hypothermia + dexmedetomidine compared to hypothermia + propofol ( $p=0.011$ ) (Table 5,

**Table 4** Gas exchange


Parameter	Group		T0	T1	T3	Group effect	Time effect	Group vs. time effect
pHa	NORMO	DEX	7.54 (7.51–7.57)	7.47 (7.40–7.49)	7.43 (7.40–7.45)	$p=0.408$	$p<0.001$	$p=0.036$
		HYPO	7.50 (7.46–7.55)	7.47 (7.38–7.49)	7.41 (7.27–7.46)			
	PRO	DEX	7.46 (7.40–7.52)	7.46 (7.36–7.49)	7.41 (7.35–7.50)			
		HYPO	7.51 (7.47–7.53)	7.49 (7.44–7.54)	7.46 (7.39–7.48)			
PaO <sub>2</sub> /FiO <sub>2</sub>	NORMO	DEX	237.50 (168.60–488.00)	381.30 (275.00–446.90)	317.50 (192.50–445.60)	$p=0.808$	$p=0.144$	$p=0.893$
		HYPO	301.30 (171.30–401.90)	428.80 (261.30–461.30)	423.80 (224.40–461.30)			
	PRO	DEX	303.50 (177.50–438.10)	385.00 (335.00–445.50)	403.80 (384.40–451.30)			
		HYPO	397.50 (190.00–473.10)	406.30 (203.80–489.90)	381.3 (187.50–450.00)			
PaCO <sub>2</sub> (mmHg)	NORMO	DEX	30.35 (26.40–35.48)	31.45 (29.68–36.18)	29.80 (28.35–31.55)	$p=0.118$	$p=0.383$	$p=0.108$
		HYPO	34.75 (32.05–38.13)	37.45 (29.10–52.00)	38.85 (33.05–47.93)			
	PRO	DEX	38.25 (32.55–41.60)	32.15 (29.35–40.70)	36.80 (27.33–48.95)			
		HYPO	34.65 (31.95–36.63)	27.60 (26.70–33.10)	36.85 (28.80–39.53)			
HCO <sub>3</sub> <sup>−</sup> (mEq/L)	NORMO	DEX	24.80 (22.78–30.23)	23.00 (21.05–24.23)	18.80 (18.13–20.98)	$p=0.418$	$p<0.001$	$p=0.181$
		HYPO	26.50 (24.98–28.48)	25.60 (22.38–30.53)	23.40 (18.15–26.15)			
	PRO	DEX	24.35 (23.23–28.98)	22.35 (20.18–24.68)	23.75 (19.03–26.03)			
		HYPO	27.40 (23.48–30.13)	22.35 (21.25–24.75)	23.30 (21.85–25.35)			

Data are expressed as median (interquartile range). *NORMO* normothermia, *HYPO* hypothermia, *DEX* dexmedetomidine, *PRO* propofol, *PaO<sub>2</sub>* arterial partial pressure of oxygen, *FiO<sub>2</sub>* fraction of inspired oxygen, *PaCO<sub>2</sub>* arterial partial pressure of carbon dioxide, *HCO<sub>3</sub><sup>−</sup>* bicarbonate

Fig. 3B). The degree of lung and kidney apoptosis, edema, and inflammation affected this final histologic injury score. In kidney, necrosis also affected the final histologic injury score. The heart histologic injury score was lower in hypothermia + dexmedetomidine compared to hypothermia + propofol ( $p=0.009$ ) as well as hypothermia + propofol compared to normothermia + propofol ( $p=0.002$ ). The degrees of heart apoptosis, edema, inflammation, and necrosis are presented in Fig. 4.

## Discussion

In this model of focal ischemic stroke, normothermia and mild hypothermia interact differently with dexmedetomidine or propofol to reduce brain, lung, and kidney damage. We found that the combination of mild hypothermia with dexmedetomidine decreased




**Fig. 2** Real-time polymerase chain reaction analysis of proinflammatory biological markers in the brain perilesional, lung, and kidney tissues. Relative gene expression was calculated as the ratio of average gene expression levels compared with the reference gene (36B4) and expressed as fold change relative to controls (C). In the brain perilesional tissue: interleukin-6 (IL-6), IL-1, intercellular adhesion molecule (ICAM), and zonula occludens-1 (ZO-1); in the lung tissue: IL-6, tumor necrosis factor- $\alpha$ , E-selectin, and ICAM; in the kidney tissue: IL-6, kidney injury molecule-1 (KIM1), ZO-1, and syndecan. Data are presented as box plots of medians and interquartile ranges with 6 animals in each group. Statistical significance was considered for  $p < 0.0125$ . DEX dexmedetomidine, HYPO hypothermia, NORMO normothermia, PRO propofol

inflammation and histologic injury score in the brain, as well as in lung and kidney. Thus, the combination of mild hypothermia or normothermia and sedatives may have different effects on brain and peripheral organs.

The present study has some strengths, including the use of a rat model that presents cerebral vasculature and physiology similar to that of humans [27]; and the analysis of the effects combining different target temperatures (mild hypothermia and normothermia) with different sedatives (propofol and dexmedetomidine) on morphology and molecular biology of brain and distal organs [28]. To date, no study has compared different target temperatures combined with different sedatives focusing not only on brain injury but also evaluating beneficial effects on lung, kidney, and heart in acute focal ischemic stroke.

### Perilesional brain tissue

The present study showed that, in the brain, under normothermia, dexmedetomidine, compared with propofol, resulted in a lower brain histologic injury score and inflammation (TNF- $\alpha$ ). Our results are in agreement with the literature [29, 30]. Indeed, dexmedetomidine, when compared with saline, decreased inflammation [31], brain water content and damage to the blood–brain barrier, thus improving neurologic function in rat model [32]. In an animal model, propofol was comparable to dexmedetomidine to minimize brain injury, since it reduced oxidative stress, apoptosis [33], microglia-mediated proinflammatory cytokines [34], as well as increased expression of heme-oxygenase-1 in ischemic penumbra and core [35].



**Fig. 3** **A** Representative photomicrographs (light microscopy) of brain, lung, and kidney stained with hematoxylin–eosin stain in normothermia propofol (NORMO + PRO), normothermia dexmedetomidine (NORMO + DEX), hypothermia propofol (HYPO + PRO), and hypothermia dexmedetomidine (HYPO + DEX) rats. Decrease in cortex neurons pyroptosis and neuropil edema (**A** arrowheads and hash, inset) were observed in the HYPO + DEX and HYPO + PRO groups. Decrease in inflammatory thickening of the alveolar septa (**E** double arrowheads, inset) and renal tubular necrosis (**I** double asterisks, inset) in the HYPO + DEX and HYPO + PRO groups; more prominent in the NORMO + DEX group. The marked decrease in pyroptosis in cortical neurons (**C** arrowheads, inset), inflammatory alveolar septa (**G** double arrowheads, inset), and renal tubular necrosis (**K** double asterisks, inset) in HYPO + DEX and HYPO + PRO rats (**D–L**). Magnification  $\times 400$ ; inset  $\times 1000$ . **B**: Brain, lung and kidney injury score. Boxes show the interquartile (25–75%) range, whiskers encompass the range (minimum to maximum), and horizontal lines represent median values of six animals/group. *DEX* dexmedetomidine, *HYPO* hypothermia, *NORMO* normothermia, *PRO* propofol. Histologic injury score in brain, lung and kidney was calculated by multiplying the severity and extent of organ injury (minimum score = 0 and maximum score = 16) and the total was calculated as the sum of each score for apoptosis, edema, inflammation, and necrosis (minimum score = 0 to maximum score = 64)

Furthermore, propofol potentiates neurologic recovery [36] and neurobehavioral outcome [37, 38] through a decrease in myeloperoxidases, nuclear factor (NF)- $\kappa$ B, cyclooxygenase (COX)-2, and TNF- $\alpha$  [39], which reduces cerebral edema and protects the blood–brain barrier. In pre-clinical studies, dexmedetomidine increased anti-inflammatory and neuroprotective effects more than propofol [40, 41], and this is in accordance to our findings; however, in the clinical setting, dexmedetomidine and propofol appeared equally effective on brain recovery and outcome [42, 43]. These differences may be explained based on the time these sedatives were administered, the type and degree of brain damage, as well as the parameters used to evaluate the efficacy of dexmedetomidine and propofol.


**Table 5** Damage scores in perilesional brain, lung, and kidney tissues

	NORMO		HYPO		Group effect
	DEX	PRO	DEX	PRO	
Brain					
Brain injury score	(12.50–19.00)	27.00 (24.00–36.00)	8.00 (6.25–8.50)	11.00 (8.50–12.50)	NORMO-PRO vs. NORMO-DEX $p=0.002$ NORMO-PRO vs. HYPO-PRO $p=0.002$ NORMO-DEX vs. HYPO-DEX $p=0.002$
Apoptosis	4.00 (4.00–6.00)	10.50 (8.25–12.00)	2.00 (1.75–2.50)	2.00 (2.00–4.00)	NORMO-PRO vs. NORMO-DEX $p=0.007$ NORMO-PRO vs. HYPO-PRO $p=0.002$ NORMO-DEX vs. HYPO-DEX $p=0.011$
Edema	4.00 (4.00–9.00)	9.00 (8.25–12.00)	3.00 (2.00–4.00)	4.00 (2.75–4.50)	NORMO-PRO vs. HYPO-PRO $p=0.004$
Inflammation	5.00 (3.00–6.00)	9.00 (8.25–12.00)	2.00 (1.00–4.00)	4.00 (3.75–4.50)	NORMO-PRO vs. NORMO-DEX $p=0.009$ NORMO-PRO vs. HYPO-PRO $p=0.004$
Necrosis	0.00 (0.00–0.00)	0.00 (0.00–0.00)	0.00 (0.00–0.00)	0.00 (0.00–0.00)	–
Lung					
Lung injury score	13.00 (10.00–17.50)	31.50 (29.75–34.75)	8.00 (5.00–10.00)	14.00 (12.75–15.00)	NORMO-PRO vs. NORMO-DEX $p=0.002$ NORMO-PRO vs. HYPO-PRO $p=0.002$ HYPO-DEX vs. HYPO-PRO $p=0.002$
Apoptosis	4.00 (4.00–5.25)	10.50 (8.75–16.00)	2.00 (2.00–4.00)	4.00 (3.75–6.00)	NORMO-PRO vs. NORMO-DEX $p=0.009$ NORMO-PRO vs. HYPO-PRO $p=0.002$
Edema	4.00 (2.00–5.25)	9.00 (7.50–10.75)	2.00 (2.00–4.00)	6.00 (4.00–6.00)	NORMO-PRO vs. HYPO-PRO $p=0.011$
Inflammation	4.00 (4.00–6.00)	12.00 (9.00–12.00)	2.00 (1.00–4.00)	4.00 (4.00–4.50)	NORMO-PRO vs. NORMO-DEX $p=0.002$ NORMO-PRO vs. HYPO-PRO $p=0.002$
Necrosis	0.00 (0.00–0.00)	0.00 (0.00–0.00)	0.00 (0.00–0.00)	0.00 (0.00–0.00)	–

**Table 5** (continued)

	NORMO		HYPO		Group effect
	DEX	PRO	DEX	PRO	
Kidney					
Kidney injury score	17.00 (15.75–19.25)	20.00 (17.25–31.75)	13.00 (11.00–15.00)	18.00 (15.25–23.50)	NORMO-DEX vs. HYPO-DEX $p = 0.007$ HYPO-DEX vs. HYPO-PRO $p = 0.011$
Apoptosis	5.00 (4.00–5.00)	5.00 (4.00–9.00)	4.00 (4.00–4.00)	4.00 (3.25–5.25)	–
Edema	4.00 (4.00–4.00)	4.00 (2.00–6.00)	2.00 (2.00–4.00)	4.00 (4.00–6.00)	–
Inflammation	4.00 (2.00–4.00)	4.00 (3.50–6.00)	1.50 (1.00–4.00)	4.00 (3.50–5.25)	–
Necrosis	4.00 (3.75–6.00)	8.00 (4.00–12.00)	4.00 (3.75–4.00)	4.00 (4.00–9.00)	–

Data are expressed as medians (interquartile range). Mann–Whitney test with Bonferroni multiple comparison between groups was adopted. Statistical significance was considered for  $p < 0.0125$ . Points of severity and extent varied between 0 (no severity/extent) and 4 (maximum severity/extent). Histology injury scores were calculated by multiplying the severity and extent of brain injury (minimum score = 0 and maximum score = 16) and was calculated as the sum of each score for apoptosis, edema, inflammation, and necrosis (minimum score = 0 to maximum score = 64). *NORMO* normothermia, *HYPO* hypothermia, *DEX* dexmedetomidine, *PRO* propofol



	NORMO		HYPO		Group effect
	DEX	PRO	DEX	PRO	
Heart injury score	14.00 (11.00–16.50)	26.00 (23.00–30.00)	13.00 (11.75–14.50)	21.50 (17.00–24.75)	HYPO-DEX vs. HYPO-PRO $p = 0.009$ NORMO-DEX vs. NORMO-PRO $p = 0.002$
Apoptosis	4.00 (3.50–4.00)	9.00 (8.00–12.00)	4.00 (3.25–4.00)	5.00 (4.00–6.75)	NORMO-DEX vs. NORMO-PRO $p = 0.002$
Edema	4.00 (2.00–4.50)	5.00 (3.50–9.00)	4.00 (2.00–4.00)	5.00 (4.00–6.00)	–
Inflammation	2.00 (1.00–4.00)	4.00 (4.00–6.00)	4.00 (2.00–4.00)	4.00 (3.50–9.00)	–
Necrosis	4.00 (3.50–6.00)	7.00 (5.00–9.00)	3.00 (2.00–4.00)	6.00 (3.50–6.75)	–

**Fig. 4** Upper panel. Histology of the heart visualized by hematoxylin–eosin staining in normothermia (NORMO), hypothermia (HYPO), propofol (PRO), dexmedetomidine (DEX) rats. Hyaline necrosis of heart fibers (A–D asterisks, inset). Magnification  $\times 400$ ; inset  $\times 1000$ . Lower panel. Data are expressed as median (interquartile range quartiles). Mann–Whitney test with Bonferroni multiple comparison between groups was adopted. A  $p$  level  $< 0.0125$  was considered statistically significant. Points for severity and extent varied between 0 (no severity/extent) to 4 (maximum severity/extent). The heart injury score was calculated by multiplying the severity and extent of injury (minimum score = 0 and maximum score = 16) and was calculated by the sum of each score for apoptosis, edema, inflammation, and necrosis (minimum score = 0 to maximum score = 64). Magnification  $\times 400$ ; inset  $\times 1000$

Previous experimental studies show that mild hypothermia reduces infarct size, improves functional outcome, and reduces brain inflammation and apoptosis [44, 45]. In this line, in the current acute ischemic stroke model, expression of TNF- $\alpha$  in the brain



and the histologic injury score were significantly reduced in mild hypothermia compared with normothermia using either propofol or dexmedetomidine. The reduced brain injury and decreased inflammation resulting from mild hypothermia with propofol seems to be explained by mechanisms associated with different pathways [12]. Dexmedetomidine associated with hypothermia reduces brain damage, improves neurological outcome, and increases the survival rate of the hippocampal CA1 neurons, compared to saline [46]. The increase in expression of ZO-1 in mild hypothermia + dexmedetomidine compared to normothermia + dexmedetomidine may be attributed to hypothermia alleviating neurocyte apoptosis [47].

#### **Peripheral organs: lung, kidney, and heart**

In the current model of acute ischemic stroke, mild hypothermia + propofol compared to normothermia + propofol reduced TNF- $\alpha$  in lung tissue. In previous experimental studies, under normothermia, 1 h of propofol infusion reduced the expression of proinflammatory mediators [48, 49] and lung injury [50]. Dexmedetomidine but not propofol reduced lung injury in experimental acute ischemic stroke [51]. The reduction of lung damage in hypothermia + dexmedetomidine has been previously observed in a model of acute lung injury [52]. As previously demonstrated in small animal models, other organs can benefit from hypothermia and dexmedetomidine [53–55]. Hypothermia + dexmedetomidine compared to hypothermia + propofol decreased kidney damage, which may be associated with reduced inflammation and oxidative stress [53] through the inhibition of different pathways [54, 55]. In the heart, the histologic injury score was lower with dexmedetomidine than propofol regardless of the temperature. Dexmedetomidine attenuates cell damage and apoptosis in H9c2 cardiomyocytes [56] and inhibits pyroptosis in myocardial ischemia–reperfusion injury in rats [57]. Propofol also reduced cardiac injury via inhibition of intrinsic apoptotic pathways [58, 59].

#### **Additional findings**

In mild hypothermia, we found that carotid flow velocities were increased with both dexmedetomidine and propofol, and mean arterial pressure was lower with dexmedetomidine. In agreement with our results, mild hypothermia increases cerebral blood flow [60], but can be associated with cardiovascular instability [61].

In our study, mild hypothermia with propofol, but not dexmedetomidine, increased Pplat, RS, but lung inflammation was lower with propofol and mild hypothermia. Differently from what reported in a previous study, under normothermia, propofol compared with pentobarbital sodium, reduces airway resistance as well as alveolar collapse in rat models [48]. These contrasting findings need further investigation.

#### **Limitations**

This study has some limitations that should be addressed. First, our model cannot reproduce the complex clinical scenario of human patients. Indeed, the craniectomy to induce focal ischemic stroke, which allows the permanent occlusion of the target vessel by thermocoagulation, has good reproducibility concerning the infarct size, but cannot be comparable to real clinical scenario [62]. Second, our findings are limited to a relatively short observation time (60 min) to hinder lung damage associated with prolonged

invasive mechanical ventilation. Third, the location and intensity of damage to the brain, lungs, kidneys and heart and the response to the target temperature, sedatives and different therapeutic conditions might be influenced by the species and size of the animals. The time frame for quantification of gene expression of 1 h, although sufficient to produce changes in mRNA expression, might not have significantly modified protein levels. Fourth, the rats were never awakened to test neurobehavioral response, but were euthanized to collect organs and investigate biomarkers associated with inflammation and histopathological findings. Fifth, the organ injury evaluation based on hematoxylin and eosin technique is relatively unspecific given that the degree of apoptosis and necrosis was not confirmed by any specific staining. Despite these limitations, this is a step forward for clinical testing of combined mild hypothermia and sedatives in acute ischemic stroke patients.

## Conclusions

In the current model of acute focal ischemic stroke, the combination of mild hypothermia with dexmedetomidine reduced brain, lung, and kidney damage.

## Abbreviations

CTRL	Control
CCA	Right internal carotid artery
DEX	Dexmedetomidine
EDV	End-diastolic velocity
FiO2	Fraction of inspired oxygen
HYPO	Hypothermia
ICAM	Intracellular adhesion molecule
IL	Interleukin
KIM	Kidney injury molecule
MAP	Mean arterial pressure
mFV	Mean flow velocity
MV	Mean velocity
NORMO	Normothermia
PEEP	Positive end-expiratory pressure
PG	Pressure gradient
PI	Pulsatility index
Pplat	Plateau pressure
PRO	Propofol
PSV	Peak systolic velocity
TNF	Tumor necrosis factor
ZO	Zonula occludens

## Acknowledgements

The authors express their gratitude to the following people from the Laboratory of Pulmonary Investigation, Carlos Chagas Filho Biophysics Institute, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil: Andre Benedito da Silva, BSc, for animal care; Arlete Fernandes, BSc, for her help with microscopy; Maira Rezende Lima, MSc, for her assistance with molecular biology analysis; and to Moira Elizabeth Shottler, mBA, Rio de Janeiro, Brazil, and Lorna O'Brien (authorserv.com) for editing assistance.

## Author contributions

DB designed the research design and was involved in acquisition of data, statistical analysis, writing and editing; ALS, NSF, GR, MAA, NNR, VLC, and MMM were involved in acquisition of data, processing and analysis of data; FFC, CR, and PLS designed the research and critically reviewed the text for intellectual content; PP and PRM designed the research design, wrote and edited the manuscript, and critically reviewed the text for intellectual content. All authors read and approved the final manuscript.

## Funding

Supported by the Brazilian Council for Scientific and Technological Development (CNPq; Brasília, Brazil), the Rio de Janeiro State Research Foundation (FAPERJ; Rio de Janeiro, Brazil; and CAPES, the Brazilian federal agency for graduate education.

## Availability of data and materials

Datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request. <https://github.com/DenBatt/DenBatt-2022-git>.

## Declarations

### Ethics approval and consent to participate

This study was approved by the Ethics Committee for the Use of Animals (CEUA-CCS-116/19) of Federal University of Rio de Janeiro, Brazil.

### Consent to publication

Not applicable.

### Competing interests

The authors declare no competing interests.

### Author details

<sup>1</sup>Anesthesiology and Critical Care, San Martino Policlinico Hospital, IRCCS for Oncology and Neurosciences, 16132 Genoa, Italy. <sup>2</sup>Department of Medicine, University of Barcelona, 08007 Barcelona, Spain. <sup>3</sup>Laboratory of Pulmonary Investigation, Carlos Chagas Filho Institute of Biophysics, Centro de Ciências da Saúde, Federal University of Rio de Janeiro, Avenida Carlos Chagas Filho, 373, Bloco G-014, Ilha Do Fundão, Rio de Janeiro, RJ 21941-902, Brazil. <sup>4</sup>Department of Physiology and Pharmacology, Biomedical Institute, Fluminense Federal University, Niterói 24220-900, Brazil. <sup>5</sup>Department of Pathology, University of São Paulo, São Paulo 05508-060, Brazil. <sup>6</sup>Laboratory of Cellular and Molecular Physiology, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro 21941-901, Brazil. <sup>7</sup>Department of Surgical Sciences and Integrated Diagnostics (DISC), University of Genoa, Genoa, Italy. <sup>8</sup>Rio de Janeiro Network On Neuroinflammation, Carlos Chagas Filho Foundation for Supporting Research in the State of Rio de Janeiro (FAPERJ), Rio de Janeiro, Brazil.

Received: 31 August 2022 Accepted: 29 November 2022

Published online: 19 December 2022

## References

- Zerna C, Thomalla G, Campbell BCV et al (2018) Current practice and future directions in the diagnosis and acute treatment of ischaemic stroke. *Lancet* 392:1247–1256. [https://doi.org/10.1016/S0140-6736\(18\)31874-9](https://doi.org/10.1016/S0140-6736(18)31874-9)
- Samary CS, Ramos AB, Maia LA et al (2018) Focal ischemic stroke leads to lung injury and reduces alveolar macrophage phagocytic capability in rats. *Crit Care* 22:249. <https://doi.org/10.1186/s13054-018-2164-0>
- Iadecola C, Buckwalter MS, Anrather J (2020) Immune responses to stroke: mechanisms, modulation, and therapeutic potential. *J Clin Invest* 130:2777–2788. <https://doi.org/10.1172/JCI135530>
- Pandharipande PP, Pun BT, Herr DL et al (2007) Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients. *JAMA* 298:2644. <https://doi.org/10.1001/jama.298.22.2644>
- Adembri C, Venturi L, Tani A et al (2006) Neuroprotective effects of propofol in models of cerebral ischemia. *Anesthesiology* 104:80–89. <https://doi.org/10.1097/0000542-200601000-00014>
- Deng H, Han HS, Cheng D et al (2003) Mild hypothermia inhibits inflammation after experimental stroke and brain inflammation. *Stroke* 34:2495–2501. <https://doi.org/10.1161/01.STR.00000091269.67384.E7>
- Chamorro Á, Dirnagl U, Urra X, Planas AM (2016) Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and inflammation. *Lancet Neurol* 15:869–881. [https://doi.org/10.1016/S1474-4422\(16\)00114-9](https://doi.org/10.1016/S1474-4422(16)00114-9)
- Neugebauer H, Schneider H, Bösel J et al (2019) Outcomes of hypothermia in addition to decompressive hemicraniectomy in treatment of malignant middle cerebral artery stroke. *JAMA Neurol* 76:571. <https://doi.org/10.1001/jamaneurol.2018.4822>
- Yenari MA, Han HS (2012) Neuroprotective mechanisms of hypothermia in brain ischaemia. *Nat Rev Neurosci* 13:267–278. <https://doi.org/10.1038/nrn3174>
- Wang F, Luo Y, Ling F et al (2010) Comparison of neuroprotective effects in ischemic rats with different hypothermia procedures. *Neurol Res* 32:378–383. <https://doi.org/10.1179/016164110X12670144526183>
- Nishina K, Akamatsu H, Mikawa K et al (1999) The effects of clonidine and dexmedetomidine on human neutrophil functions. *Anesth Analg* 88:452–458. <https://doi.org/10.1097/0000539-199902000-00042>
- Peters CE, Korkok J, Gelb AW, Wilson JX (2001) Anesthetic concentrations of propofol protect against oxidative stress in primary astrocyte cultures. *Anesthesiology* 94:313–321. <https://doi.org/10.1097/0000542-200102000-00022>
- van der Worp HB, Sena ES, Donnan GA et al (2007) Hypothermia in animal models of acute ischaemic stroke: a systematic review and meta-analysis. *Brain* 130:3063–3074. <https://doi.org/10.1093/brain/awm083>
- Barros Heil LB, Santos CL, Santos RS et al (2016) The effects of short-term propofol and dexmedetomidine on lung mechanics, histology, and biological markers in experimental obesity. *Anesth Analg* 122:1015–1023. <https://doi.org/10.1213/ANE.0000000000001114>
- Samary CS, Santos RS, Santos CL et al (2015) Biological impact of transpulmonary driving pressure in experimental acute respiratory distress syndrome. *Anesthesiology* 123:423–433. <https://doi.org/10.1097/ALN.0000000000000716>
- Uhlir C, Krause H, Koch T et al (2015) Anesthesia and monitoring in small laboratory mammals used in anesthesiology, respiratory and critical care research: a systematic review on the current reporting in top-10 impact factor ranked journals. *PLoS ONE* 10:e0134205. <https://doi.org/10.1371/journal.pone.0134205>
- Jedrzejewski T, Piotrowski J, Kowalczywska M et al (2015) Polysaccharide peptide from *Coriolus versicolor* induces interleukin 6-related extension of endotoxin fever in rats. *Int J Hyperther* 31:626–634. <https://doi.org/10.3109/02656736.2015.1046953>
- Wu X, Stezoski J, Safar P et al (2003) After spontaneous hypothermia during hemorrhagic shock, continuing mild hypothermia (34°C) improves early but not late survival in rats. *J Trauma Inj Infect Crit Care* 55:308–316. <https://doi.org/10.1097/01.TA.0000079366.23533.1E>

19. Krafft P, Frietsch T, Lenz C et al (2000) Mild and moderate hypothermia ( $\alpha$ -Stat) do not impair the coupling between local cerebral blood flow and metabolism in rats. *Stroke* 31:1393–1401. <https://doi.org/10.1161/01.STR.31.6.1393>
20. García-Villalón AL, Roda JM, Alvarez F et al (1992) Carotid blood flow in anesthetized rats: effects of carotid ligation and anastomosis. *Microsurgery* 13:258–261. <https://doi.org/10.1002/micr.1920130513>
21. Andrews PJD, Sinclair HL, Rodríguez A et al (2015) Hypothermia for intracranial hypertension after traumatic brain injury. *N Engl J Med* 373:2403–2412. <https://doi.org/10.1056/NEJMoa1507581>
22. Jamme M, Mosnino E, Hayon J, Franchineau G (2021) Fatal cerebral venous sinus thrombosis after COVID-19 vaccination. *Intensive Care Med* 47:790–791. <https://doi.org/10.1007/s00134-021-06425-y>
23. Chuang S-Y, Cheng H-M, Bai C-H et al (2016) Blood pressure, carotid flow pulsatility, and the risk of stroke. *Stroke* 47:2262–2268. <https://doi.org/10.1161/STROKEAHA.116.013207>
24. Albayrak R, Degirmenci B, Acar M et al (2007) Doppler sonography evaluation of flow velocity and volume of the extracranial internal carotid and vertebral arteries in healthy adults. *J Clin Ultrasound* 35:27–33. <https://doi.org/10.1002/jcu.20301>
25. Kremer H, Baron-Menguy C, Tesse A et al (2011) Human serum albumin improves endothelial dysfunction and survival during experimental endotoxemia: concentration-dependent properties\*. *Crit Care Med* 39:1414–1422. <https://doi.org/10.1097/CCM.0b013e318211ff6e>
26. Akamine R, Yamamoto T, Watanabe M et al (2007) Usefulness of the 5' region of the cDNA encoding acidic ribosomal phosphoprotein P0 conserved among rats, mice, and humans as a standard probe for gene expression analysis in different tissues and animal species. *J Biochem Biophys Methods* 70:481–486. <https://doi.org/10.1016/j.jbbm.2006.11.008>
27. Yamori Y, Horie R, Handa H et al (1976) Pathogenetic similarity of strokes in stroke-prone spontaneously hypertensive rats and humans. *Stroke* 7:46–53. <https://doi.org/10.1161/01.STR.7.1.46>
28. Pontén U, Ratneson RA, Salford LG, Siesjö BK (1973) Optimal freezing conditions for cerebral metabolites in rats. *J Neurochem* 21:1127–1138. <https://doi.org/10.1111/j.1471-4159.1973.tb07567.x>
29. Huang C, Ng OT-W, Chu JM-T et al (2019) Differential effects of propofol and dexmedetomidine on neuroinflammation induced by systemic endotoxin lipopolysaccharides in adult mice. *Neurosci Lett* 707:134309. <https://doi.org/10.1016/j.neulet.2019.134309>
30. Xing N, Xing F, Li Y et al (2020) Dexmedetomidine improves propofol-induced neuronal injury in rat hippocampus with the involvement of miR-34a and the PI3K/Akt signaling pathway. *Life Sci* 247:117359. <https://doi.org/10.1016/j.lfs.2020.117359>
31. Zhu Y, Li S, Liu J et al (2019) Role of JNK signaling pathway in dexmedetomidine post-conditioning-induced reduction of the inflammatory response and autophagy effect of focal cerebral ischemia reperfusion injury in rats. *Inflammation* 42:2181–2191. <https://doi.org/10.1007/s10753-019-01082-2>
32. Zhou W, Zhang Y, Jiao Y et al (2021) Dexmedetomidine maintains blood–brain barrier integrity by inhibiting Drp1-related endothelial mitochondrial dysfunction in ischemic stroke. *Acta Biochim Biophys Sin (Shanghai)* 53:1177–1188. <https://doi.org/10.1093/abbs/gmab092>
33. Ma Z, Li K, Chen P et al (2020) Propofol attenuates inflammatory damage via inhibiting NLRP1-Casp1-Casp6 signaling in ischemic brain injury. *Biol Pharm Bull* 43:1481–1489. <https://doi.org/10.1248/bpb.b20-00050>
34. Yu H, Wang X, Kang F et al (2018) Propofol attenuates inflammatory damage on neurons following cerebral infarction by inhibiting excessive activation of microglia. *Int J Mol Med* 43:452–460. <https://doi.org/10.3892/ijmm.2018.3974>
35. Liang C, Cang J, Wang H, Xue Z (2013) Propofol attenuates cerebral ischemia/reperfusion injury partially using heme oxygenase-1. *J Neurosurg Anesthesiol* 25:311–316. <https://doi.org/10.1097/ANA.0b013e31828c6af5>
36. Wang Y, Tian D, Zhao Y et al (2021) Propofol protects regulatory T cells, suppresses neurotoxic astrogliosis, and potentiates neurological recovery after ischemic stroke. *Neurosci Bull* 37:725–728. <https://doi.org/10.1007/s12264-021-00653-4>
37. Ji F-T, Liang J-J, Miao L-P et al (2015) Propofol post-conditioning protects the blood brain barrier by decreasing matrix metalloproteinase-9 and aquaporin-4 expression and improves the neurobehavioral outcome in a rat model of focal cerebral ischemia-reperfusion injury. *Mol Med Rep* 12:2049–2055. <https://doi.org/10.3892/mmr.2015.3585>
38. Lee JH, Cui HS, Shin SK et al (2013) Effect of propofol post-treatment on blood-brain barrier integrity and cerebral edema after transient cerebral ischemia in rats. *Neurochem Res* 38:2276–2286. <https://doi.org/10.1007/s11064-013-1136-7>
39. Shi S, Yang W, Chen Y et al (2014) Propofol reduces inflammatory reaction and ischemic brain damage in cerebral ischemia in rats. *Neurochem Res* 39:793–799. <https://doi.org/10.1007/s11064-014-1272-8>
40. Lv J, Wei Y, Chen Y et al (2017) Dexmedetomidine attenuates propofol-induced neuroapoptosis partly via the activation of the PI3K/Akt/GSK3 $\beta$  pathway in the hippocampus of neonatal rats. *Environ Toxicol Pharmacol* 52:121–128. <https://doi.org/10.1016/j.etap.2017.03.017>
41. Wang Y, Wu C, Han B et al (2016) Dexmedetomidine attenuates repeated propofol exposure-induced hippocampal apoptosis, PI3K/Akt/Gsk-3 $\beta$  signaling disruption, and juvenile cognitive deficits in neonatal rats. *Mol Med Rep* 14:769–775. <https://doi.org/10.3892/mmr.2016.5321>
42. James ML, Olson DM, Graffagnino C (2012) A pilot study of cerebral and haemodynamic physiological changes during sedation with dexmedetomidine or propofol in patients with acute brain injury. *Anaesth Intensive Care* 40:949–957. <https://doi.org/10.1177/0310057X1204000605>
43. Owusu KA, Kurczewski L, Armahizer MJ et al (2020) DEXmedetomidine compared to PROpofol in NEurocritical Care [DEXPRONE]: a multicenter retrospective evaluation of clinical utility and safety. *J Crit Care* 60:79–83. <https://doi.org/10.1016/j.jccrc.2020.07.021>
44. Kollmar R, Blank T, Han JL et al (2007) Different degrees of hypothermia after experimental stroke. *Stroke* 38:1585–1589. <https://doi.org/10.1161/STROKEAHA.106.475897>
45. Dumitrascu OM, Lamb J, Lyden PD (2016) Still cooling after all these years: meta-analysis of pre-clinical trials of therapeutic hypothermia for acute ischemic stroke. *J Cereb Blood Flow Metab* 36:1157–1164. <https://doi.org/10.1177/0271678X16645112>

46. Sato K, Kimura T, Nishikawa T et al (2010) Neuroprotective effects of a combination of dexmedetomidine and hypothermia after incomplete cerebral ischemia in rats. *Acta Anaesthesiol Scand* 54:377–382. <https://doi.org/10.1111/j.1399-6576.2009.02139.x>
47. Lu J, Liu L, Zhu J et al (2019) Hypothermic properties of dexmedetomidine provide neuroprotection in rats following cerebral ischemia-reperfusion injury. *Exp Ther Med* 18:817–825. <https://doi.org/10.3892/etm.2019.7613>
48. Cavalcanti V, Santos CL, Samary CS et al (2014) Effects of short-term propofol and dexmedetomidine on pulmonary morphofunction and biological markers in experimental mild acute lung injury. *Respir Physiol Neurobiol* 203:45–50. <https://doi.org/10.1016/j.resp.2014.08.008>
49. Tang J, Chen X, Tu W et al (2011) Propofol inhibits the activation of p38 through up-regulating the expression of annexin A1 to exert its anti-inflammation effect. *PLoS ONE* 6:e27890. <https://doi.org/10.1371/journal.pone.0027890>
50. Bae H-B, Li M, Lee S-H et al (2013) Propofol attenuates pulmonary injury induced by collapse and reventilation of lung in rabbits. *Inflammation* 36:680–688. <https://doi.org/10.1007/s10753-012-9592-9>
51. Sousa GC, Fernandes MV, Cruz FF et al (2021) Comparative effects of dexmedetomidine and propofol on brain and lung damage in experimental acute ischemic stroke. *Sci Rep* 11:23133. <https://doi.org/10.1038/s41598-021-02608-1>
52. Chen X, Li L, Hu J et al (2017) Anti-inflammatory effect of dexmedetomidine combined with hypothermia on acute respiratory distress syndrome in rats. *J Surg Res* 216:179–184. <https://doi.org/10.1016/j.jss.2017.05.014>
53. Sidonia B, Horatiu R, Vlad L et al (2020) Hypothermia effects on liver and kidney oxidative stress parameters in an experimental model of sepsis in rats. *J Vet Res* 64:187–195. <https://doi.org/10.2478/jvetres-2020-0004>
54. Feng X, Guan W, Zhao Y et al (2019) Dexmedetomidine ameliorates lipopolysaccharide-induced acute kidney injury in rats by inhibiting inflammation and oxidative stress via the GSK-3 $\beta$ /Nrf2 signaling pathway. *J Cell Physiol* 234:18994–19009. <https://doi.org/10.1002/jcp.28539>
55. Akpınar H, Akpınar O (2018) The effects of dexmedetomidine on biomarkers of oxidative stress and antioxidants in kidney. *Bratislava Med J* 119:476–480. [https://doi.org/10.4149/BLL\\_2018\\_087](https://doi.org/10.4149/BLL_2018_087)
56. Zhu Z, Ling X, Zhou H et al (2020) Dexmedetomidine attenuates cellular injury and apoptosis in H9c2 cardiomyocytes by regulating p-38MAPK and endoplasmic reticulum stress. *Drug Des Devel Ther* 14:4231–4243. <https://doi.org/10.2147/DDDT.S265970>
57. Zhong Y, Li Y-P, Yin Y-Q et al (2020) Dexmedetomidine inhibits pyroptosis by down-regulating miR-29b in myocardial ischemia reperfusion injury in rats. *Int Immunopharmacol* 86:106768. <https://doi.org/10.1016/j.intimp.2020.106768>
58. Zhao L, Zhuang J, Wang Y et al (2019) Propofol ameliorates H9c2 cells apoptosis induced by oxygen glucose deprivation and reperfusion injury via inhibiting high levels of mitochondrial fusion and fission. *Front Pharmacol* 10:61. <https://doi.org/10.3389/fphar.2019.00061>
59. Wang Y, Zhang K, Qi X et al (2020) Effects of propofol on LC3II and mTOR/p-mTOR expression during ischemia-reperfusion myocardium injury in rats with type 2 diabetes mellitus. *Exp Ther Med* 19:2441–2448. <https://doi.org/10.3892/etm.2020.8499>
60. Mahmood MA (2005) Transcranial Doppler ultrasonographic evaluation of middle cerebral artery hemodynamics during mild hypothermia. *J Neuroimaging* 15:336–340. <https://doi.org/10.1177/1051228405279042>
61. Ezzati M, Kawano G, Rocha-Ferreira E et al (2017) Dexmedetomidine combined with therapeutic hypothermia is associated with cardiovascular instability and neurotoxicity in a piglet model of perinatal asphyxia. *Dev Neurosci* 39:156–170. <https://doi.org/10.1159/000458438>
62. Tamura A, Graham DI, McCulloch J, Teasdale GM (1981) Focal cerebral ischaemia in the rat: 1. Description of technique and early neuropathological consequences following middle cerebral artery occlusion. *J Cereb Blood Flow Metab* 1:53–60. <https://doi.org/10.1038/jcbfm.1981.6>

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Submit your manuscript to a SpringerOpen<sup>®</sup> journal and benefit from:**

- Convenient online submission
- Rigorous peer review
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

---

Submit your next manuscript at ► [springeropen.com](https://www.springeropen.com)